leisure time -WSS

leisure time

author：entertainment 2025-09-05 11:32:33 - browse：414

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

focus

hotspot

WSS

Georgia court denies Trump's request to quash DA's 2020 election probe

Biohaven protein

Can CDC director Mandy Cohen drive consensus in Washington?

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Woman gored by Bison at Yellowstone

Heat waves linked to early deliveries, preterm births in new study

explore

leisure time

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Heat waves linked to early deliveries, preterm births in new study

Tori Bowie and the unacceptable rates of Black maternal death

First Opinion Podcast: What happens when kids become caregivers?

Jerome Adams on the need for new antivirals for Covid

Involuntary treatment for addiction doesn't work

Apple is now the first public company to be valued at $3 trillion

Does aspartame cause cancer? What new WHO guidance says

Moonlake's readout produced a cash windfall. Risks remain

Care demand spikes challenge UnitedHealth’s provider arm

Wikipedia

Europe sees delivery challenges ahead on Alzheimer's therapies

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Latest bird flu infection made farmworker sicker than earlier cases

Scientists successfully use ultrasound imaging to map brain activity

Argenx drug significantly slows progression of nerve disorder

Does aspartame cause cancer? What new WHO guidance says

focus

Wikipedia

hotspot

hotspot